EGFR mutation + MET mutation
|
NSCLC
|
EGFR mutation + MET mutation
|
NSCLC
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
EGFR mutation + MET mutation
|
NSCLC
|
EGFR mutation + MET mutation
|
NSCLC
|
osimertinib + savolitinib Sensitive: C3 – Early Trials
|
osimertinib + savolitinib Sensitive: C3 – Early Trials
|